Abstract
Pharmacotherapy is effective in decreasing the incidence of osteoporotic fracture, morbidity, and mortality. This benefit is pronounced in patients at highest risk for fracture: those with prior osteoporotic fracture, very low bone mineral density, or receiving chronic corticosteroid treatment. We review the best pharmacotherapeutic options currently available for treating osteoporosis.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Absorptiometry, Photon
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Bone Density Conservation Agents / therapeutic use
-
Denosumab
-
Humans
-
Osteoporosis / drug therapy*
-
Osteoporotic Fractures / epidemiology
-
RANK Ligand / therapeutic use
-
Risk Factors
-
Selective Estrogen Receptor Modulators / therapeutic use
-
Teriparatide / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bone Density Conservation Agents
-
RANK Ligand
-
Selective Estrogen Receptor Modulators
-
Teriparatide
-
Denosumab